ArticleMetabolism open2026
Curcumin modulates the adipose FBN1-Asprosin axis and improves metabolic dysfunction in a rat model of type 2 diabetes.
Article in Metabolism open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asprosin, a glucogenic adipokine derived from the C-terminal region of profibrillin-1 encoded by Methods: Forty male Wistar rats were randomly allocated to four groups (n = 10/group): control, curcumin, T2DM, and T2DM + curcumin. T2DM was induced by high-fat diet feeding followed by low-dose streptozotocin administration. Diabetic rats received curcumin (300 mg/kg/day) by oral gavage for eight weeks. Body weight, fasting blood glucose, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR) were assessed. Serum asprosin concentrations were determined using ELISA, and Results: Compared with controls, diabetic rats exhibited significantly higher body weight, fasting blood glucose, fasting insulin, HOMA-IR, adipose tissue Conclusion: Curcumin supplementation improves metabolic abnormalities and attenuates the adipose FBN1-asprosin axis in experimental T2DM. These findings suggest that modulation of FBN1-asprosin signaling may contribute to the metabolic effects of curcumin and warrants further mechanistic investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.